Longeveron

87 articles with Longeveron

• Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

  5/13/2022

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter ended March 31, 2022.

• 

  ADC, Adimab and Longeveron Begin New Leadership Chapters

  5/10/2022

  Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.

• Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022Live conference call at 8:30 a.m. EST

  5/9/2022

  Longeveron Inc. today announced that the Company will release its first quarter 2022 financial results on Friday, May 13, 2022 before the open of the U.S. financial markets.

• Longeveron Announces CEO Transition - May 09, 2022

  5/9/2022

  Longeveron Inc. announced the resignation of Chief Executive Officer Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities.

• Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference

  4/14/2022

  Longeveron Inc. announced today its Chief Science Officer, Co-Founder, and Chairman, Joshua Hare, M.D., F.A.C.C., F.A.H.A. will be presenting at the Longevity Leaders World Congress in April.

• Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical OfficerDr. Min will lead global clinical development and regulatory strategy

  4/5/2022

  Longeveron Inc. announced the addition of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer, effective April 4, 2022.

• 

  Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn's Bad Week

  4/4/2022

  It was a particularly busy week for clinical trial announcements. Let's take a look.

• Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association

  3/31/2022

  Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association.

• Longeveron Presents at Second Euro-Geroscience Conference

  3/24/2022

  Longeveron Inc. announced that management presented at the Second Euro-Geroscience Conference, being held from March 24-25, 2022 virtually and in Toulouse, France, and at a pre-meeting task force.

• Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

  3/15/2022

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022.

• Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

  3/11/2022

  Longeveron Inc. (NASDAQ: LGVN) (the “Company,” “Longeveron” or “we,” “us,” or “our”), a clinical stage biopharmaceutical company developing cellular therapies for chronic, aging-related and life-threatening conditions, today reported recent business highlights and key upcoming catalysts for 2022, and its financial results for the fourth quarter and full year 2021.

• Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

  3/7/2022

  Longeveron Inc. today announced that the Company will release its fourth quarter and year-end 2021 financial results on Friday, March 11, 2022 before the open of U.S. financial markets.

• Longeveron to Present at Q1 Virtual Investor Summit Conference

  3/2/2022

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Q1 Virtual Investor Summit on Tuesday, March 8, 2022.

• Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

  2/17/2022

  Longeveron Inc. announced today the appointment of Todd Girolamo to its Board of Directors.

• Longeveron to Participate in Phacilitate Advanced Therapies WeekLongeveron management will present live in multiple sessions at the Advanced Therapies Week at the Miami Beach Convention Center

  1/25/2022

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will be speaking and participating in several panel and presentation sessions during Phacilitate’s Advanced Therapies Week from January 25-28, 2022 in Miami Beach, FL.

• Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

  1/12/2022

  Longeveron Inc. announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s DiseaseTrial designed to obtain safety and efficacy data of single and multiple dosing regimen

  1/5/2022

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD).

• Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference

  1/4/2022

  Longeveron Inc. announced that Geoff Green, Chief Executive Officer of Longeveron, will present at the H.C. Wainwright & Co. BioConnect 2022 Virtual Conference, and participate in a panel discussion moderated by Dr. Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration.

• Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

  12/6/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.